DNM1L and MERRF: Consecutive MRIs were performed in 17 patients and imaging evidence of disease progression was present in 11 patients [six patients with MELAS, two patients with POLG1, and the patients with MERRF, exosome component 3 (EXOSC3), and dynamin-like protein 1 (DNM1L)].